A population-based resource for the prioritization of rare variants of unknown significance in clinical genomics
- 1UQAC
Abstract
Rare diseases represent a major public health challenge because they are often associated with severe phenotypes, yet many causal variants remain undiscovered. Founder populations provide a unique opportunity to identify disease-causing variants through the local enrichment of rare alleles. Using whole-genome sequencing data from individuals in the Saguenay-Lac-Saint-Jean population, enriched variants were identified and their founder status was assessed through identity-by-descent sharing. Variant impact was evaluated using functional prediction tools without relying on prior clinical classification. A total of 131 founder variants of interest were identified, most of which would likely have been overlooked by conventional approaches based on existing clinical annotations. We developed a web-based platform that facilitates clinician access to the latest interpretation of their genetic variants of interest. These findings demonstrate that potentially pathogenic variants can remain undetected even in extensively studied founder populations. More broadly, they highlight the value of population structure-based approaches for uncovering rare disease variants and improving the characterization of genetic disease risk across human populations.
Related
- A case of renal hypouricemia type 1 associated with compound heterozygous URAT1/SLC22A12 variants A209V and F379L: clinical evidence for their pathogenic significance
- The clinical significance of the modified Naples prognostic score for prostate cancer: a population-based study.
- Utilizing a Variant Prioritization Approach to Explore Genetic Variants in Cervical Cancer Cases among Malawian Women
- Population-specific molecular features and clinical significance of urinary tumor DNA mutations in Chinese patients with newly diagnosed non-muscle-invasive bladder cancer.
- Investigating the pathogenicity of missense spliceogenic variants using whole-genome sequencing, RNA-sequencing, and proteomics data from population and clinical research cohorts
BibTeX
@misc{tremblay2026populationbased,
title = {{A population-based resource for the prioritization of rare variants of unknown significance in clinical genomics}},
author = {S. Tremblay and C. Moreau and G.-P. Morin and C. Laprise and S. L. Girard},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.03.26367175},
url = {https://www.medrxiv.org/content/10.64898/2026.11.03.26367175v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - A population-based resource for the prioritization of rare variants of unknown significance in clinical genomics
AU - S. Tremblay
AU - C. Moreau
AU - G.-P. Morin
AU - C. Laprise
AU - S. L. Girard
PY - 2026
DA - 2026/11/03
PB - medRxiv
DO - 10.64898/2026.11.03.26367175
UR - https://www.medrxiv.org/content/10.64898/2026.11.03.26367175v1
AB - Rare diseases represent a major public health challenge because they are often associated with severe phenotypes, yet many causal variants remain undiscovered. Founder populations provide a unique opportunity to identify disease-causing variants through the local enrichment of rare alleles. Using whole-genome sequencing data from individuals in the Saguenay-Lac-Saint-Jean population, enriched variants were identified and their founder status was assessed through identity-by-descent sharing. Variant impact was evaluated using functional prediction tools without relying on prior clinical classification. A total of 131 founder variants of interest were identified, most of which would likely have been overlooked by conventional approaches based on existing clinical annotations. We developed a web-based platform that facilitates clinician access to the latest interpretation of their genetic variants of interest. These findings demonstrate that potentially pathogenic variants can remain undetected even in extensively studied founder populations. More broadly, they highlight the value of population structure-based approaches for uncovering rare disease variants and improving the characterization of genetic disease risk across human populations.
ER -